| PubMed |
Abstract |
RScore(About this table) |
| 16412632 |
Garino C, Pietrancosta N, Laras Y, Moret V, Rolland A, Quelever G, Kraus JL: BACE-1 inhibitory activities of new substituted phenyl-piperazine coupled to various heterocycles: chromene, coumarin and quinoline. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1995-9. Epub 2006 Jan 18.
|
164(2,2,2,4) |
Details |
| 16821787 |
Garino C, Tomita T, Pietrancosta N, Laras Y, Rosas R, Herbette G, Maigret B, Quelever G, Iwatsubo T, Kraus JL: Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. J Med Chem. 2006 Jul 13;49(14):4275-85.
Variable temperature NMR and modeling studies are consistent with the obtained biological data, since these studies confirmed that introduction at the N (4)-position of the piperazine ring allows productive interactions within the BACE-1 active site, which appear to be determinative for high BACE-1 inhibitory activity. |
84(1,1,1,4) |
Details |
| 20347593 |
Cumming J, Babu S, Huang Y, Carrol C, Chen X, Favreau L, Greenlee W, Guo T, Kennedy M, Kuvelkar R, Le T, Li G, McHugh N, Orth P, Ozgur L, Parker E, Saionz K, Stamford A, Strickland C, Tadesse D, Voigt J, Zhang L, Zhang Q: Piperazine sulfonamide BACE1 inhibitors: Design, synthesis, and in vivo characterization. Bioorg Med Chem Lett. 2010 Mar 12.
|
62(0,2,2,2) |
Details |
| 18770069 |
Laras Y, Garino C, Dessolin J, Weck C, Moret V, Rolland A, Kraus JL: New N (4)-substituted piperazine naphthamide derivatives as BACE-1 inhibitors. J Enzyme Inhib Med Chem. 2009 Feb;24(1):181-7.
|
62(0,2,2,2) |
Details |
| 14692784 |
Park H, Lee S: Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. J Am Chem Soc. 2003 Dec 31;125(52):16416-22.
Thus, both MD and docking studies suggest that the role of hydrogen bond acceptor for the hydroxyl and piperazine groups of the inhibitors should be played by Asp228 instead of Asp32. |
4(0,0,0,4) |
Details |